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Morphologic Variants of
Familial Arrhythmogenic Right
Ventricular Dysplasia/Cardiomyopathy
A Genetics–Magnetic Resonance Imaging Correlation Study
Darshan Dalal, MD, MPH,* Harikrishna Tandri, MD,* Daniel P. Judge, MD,* Nuria Amat, MS,*
Robson Macedo, MD,† Rahul Jain, MD,* Crystal Tichnell, MGC,* Amy Daly, MS,*
Cynthia James, PHD, SCM,* Stuart D. Russell, MD,* Theodore Abraham, MD,*
David A. Bluemke, MD, PHD,‡ Hugh Calkins, MD*
Baltimore and Bethesda, Maryland
Objectives The purpose of this study was to determine the extent of left ventricular (LV) involvement in individuals predis-
posed to developing arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C), and to investigate
novel morphologic variants of ARVD/C.
Background The discovery of desmosomal mutations associated with ARVD/C has led researchers to hypothesize equal right
ventricular (RV) and LV affliction in the disease process.
Methods Thirty-eight (age 30  17 years; 18 males) family members of 12 desmosomal mutation-carrying ARVD/C pro-
bands underwent genotyping and cardiac magnetic resonance imaging (CMR). The CMR investigators were
blinded to clinical and genetic data.
Results Twenty-five individuals had mutations in PKP2, DSP, and/or DSG2 genes. RV abnormalities were associated with
the presence of mutation(s) and with disease severity determined by criteria (minor  1; major  2) points for
ARVD/C diagnosis. The only LV abnormality detected, the presence of intramyocardial fat, was present in 4 indi-
viduals. Each of these individuals was a mutation carrier, whereas 1 had no previously described ARVD/C-related
abnormality. On detailed CMR, a focal “crinkling” of the RV outflow tract and subtricuspid regions
(“accordion sign”) was observed in 60% of the mutation carriers and none of the noncarriers (p  0.001). The
sign was present in 0%, 37%, 71%, and 75% of individuals who met 1, 2, 3, and 4 criteria points, respectively
(p  0.01).
Conclusions Despite a possible LV involvement in ARVD/C, the overall LV structure and function are well preserved. Indepen-
dent LV involvement is of rare occurrence. The accordion sign is a promising tool for early diagnosis of ARVD/C.
Its diagnostic utility should be confirmed in larger cohorts. (J Am Coll Cardiol 2009;53:1289–99) © 2009 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.12.045i
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ccepted December 3, 2008.cally by right ventricular (RV) dysfunction and ventricular
achycardia (1–4) and histopathologically by fibrofatty re-
lacement of the myocardium (5). Recent literature has
emonstrated the role of mutations in genes encoding
See page 1300
ardiac desmosomal proteins such as desmoplakin, plako-
lobin, plakophilin-2, and desmoglein-2 in the develop-
ent of ARVD/C (6–17). Although ARVD/C has been
onsidered primarily as a right-sided cardiomyopathy, the
rowing evidence supporting the desmosomal origin of
RVD/C has led investigators to hypothesize a concomitant
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(LV) involvement in these patients
(18). The Task Force criteria that
are widely applied to ascertain the
diagnosis of ARVD/C were pub-
lished in 1994 and were designed
to specifically exclude LV disease
(19).
The purpose of this study was
2-fold. First, our study was aimed
at determining the presence and
extent of LV involvement in indi-
viduals predisposed to developing
ARVD/C. The hypothesis of the
study was that family members
carrying mutations in genes encod-
ing desmosomal proteins would be
equally likely to develop right- or
left-sided cardiomyopathy. The
secondary aim of the study was to
dentify the early morphologic variants of ARVD/C and to
xamine their incremental value in the diagnosis of ARVD/C.
ardiac magnetic resonance imaging (CMR), which has been
eveloped as an important tool for the noninvasive evaluation
f the disease, was used to ascertain the morphologic variants
f both ventricles (20–23).
ethods
atient recruitment, evaluation, and diagnosis. The
tudy population was identified from the Johns Hopkins
RVD Registry. The Johns Hopkins ARVD Registry was
stablished in 1999 with the goal of gaining insights into the
iagnosis, genetic basis, and clinical course of patients with
nown or suspected ARVD/C. All patients included in this
egistry provided written informed consent to participate in
linical and research genetic screening. The study protocol
as approved by the Johns Hopkins Medicine Institutional
eview Board. As a routine protocol of the registry, after
iagnosis of an ARVD/C patient, all family members of the
atient are invited to undergo a screening protocol for
RVD/C. The screening protocol includes obtaining rele-
ant medical history, noninvasive clinical testing for ascer-
ainment of the Task Force criteria, and genetic sequencing
o identify possible mutations in 1 or more genes encoding
esmosomal proteins.
For the purpose of the present study, family members of
robands with 1 or more mutations in genes encoding
lakophilin-2 (PKP2), desmoplakin (DSP), and/or
esmoglein-2 (DSG2), were included. The probands were
nly used for the purpose of identifying the family members,
nd were excluded in all further analyses. Families in which
one of the family members underwent CMR were excluded.
Patients were evaluated as described previously (4). For
ach patient, medical history and family history were ob-
Abbreviations
and Acronyms
ARVD/C  arrhythmogenic
right ventricular
dysplasia/cardiomyopathy
CMR  cardiac magnetic
resonance imaging
EDV  end-diastolic volume
EF  ejection fraction
ESV  end-systolic volume
LV  left ventricle/
ventricular
ROC  receiver-operating
characteristic
RV  right ventricle/
ventricular
RVOT  right ventricular
outflow tractained. Subsequently, each patient underwent noninvasive rlinical testing, including electrocardiogram, signal-
veraged electrocardiogram, Holter monitoring, and CMR.
iagnosis of ARVD/C was established based on the criteria
et by the Task Force of the Working Group of Myocardial
nd Pericardial Disease of the European Society of Cardiology
nd of the Scientific Council on Cardiomyopathies of the
nternational Society and Federation of Cardiology (19).
MR. A detailed CMR was performed for the entire study
opulation irrespective of their genetic or clinical findings.
MRs were performed according to standard protocols for
iagnosis of ARVD/C (22). All CMR datasets were ob-
ained on a 1.5-T scanner (CV/i, GE Medical Systems,
aukesha, Wisconsin) and included both fast spin-echo
nd gradient-echo sequences. Fat- and nonfat-suppressed
ast spin-echo sequences were acquired in the axial and
hort-axis planes with breath-hold double-inversion recov-
ry blood suppression pulses. The repetition time was 1 or
R-R intervals, and the time to excitation was 10 ms. The
lice thickness was 5 mm and slice gap 5 mm. The matrix
nd field of view were 256  256 and 24 cm, respectively.
radient echo sequences were acquired in the axial and
hort-axis planes using breath-hold steady-state free preces-
ion imaging. The flip angle was 40°, and time to excitation
as set to minimum. For steady-state free precession
maging, the slice thickness was 8 mm with a slice gap of 2
m. The matrix and field of view were 256  160 and 36
m, respectively. A phased array cardiac coil was used for all
he studies. The datasets were transferred to an Advantage
indows workstation (GE Medical Systems) for analysis.
adolinium-enhanced CMRs were reviewed for evidence
f delayed enhancement in any of the RV or LV segments.
fter intravenous administration of a CMR contrast agent
0.2 mmol/kg of gadodiamide [Omniscan, Amersham
ealth, Princeton, New Jersey]), inversion recovery pre-
ared breath-hold cine gradient-echo images were obtained
0 min after contrast agent injection. Breath-hold
-dimensional imaging (7.2/3.2; inversion time optimized
50 to 200 ms; flip angle, 25°; slice thickness, 8 mm; slice
ap, 2 mm; number of excitations, 2; matrix, 256  192;
nd field of view, 360  270 mm) scans were obtained in
he short-axis and axial planes at 10-mm intervals covering
he entire RV and LV.
Quantitative analysis was performed using the software
rogram MASS (Medis, Leiden, the Netherlands). End-
ystolic image was defined visually as the one with the
mallest ventricular cavity size and end-diastolic image, as
he first image after the R-wave trigger. Quantitative CMR
arameters included end-systolic volume (ESV), end-
iastolic volume (EDV), and ejection fraction (EF) of both
entricles.
For qualitative assessment, the RV was divided into 4
egions: 1) base; 2) mid-cavity; 3) apex; and 4) right
entricular outflow tract (RVOT). The LV was divided into
regions based on the 17-segment model (24), so that
egments 1 to 6 represented the base, segments 7 to 12
epresented the midcavity, segments 13 to 16 represented
t
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April 14, 2009:1289–99 Genetics and CMR in Familial ARVD/Che apical region, and segment 17 represented the apex.
ualitative CMR parameters included globally impaired
unction, hypokinesia/akinesia, intramyocardial fat, and de-
ayed enhancement of both ventricles.
Each segment of both ventricles was carefully examined
o determine the presence of typical (Online Appendix) and
ovel morphologic variants in both ventricles. The CMR
eader was blinded to other clinical and genetic data for all
atients.
enotype analysis. For each ARVD/C proband, genomic
eoxyribonucleic acid (DNA) was extracted from leukocytes
resent in whole blood using QIAmp DNA blood maxi kits
Qiagen, Inc., Valencia, California). Amplification of exons
n either side of DSP, PKP2, and DSG2 was performed as
reviously described, with primer sequence (8,11–13,17,25).
idirectional sequence chromatography was performed us-
ng an Applied Biosystems 3730 DNA Analyzer (Foster
ity, California). Analysis of chromatograms was per-
ormed using Sequencher 4.2.2 (Gene Codes Corp., Ann
rbor, Michigan). Novel mutations were analyzed in a
opulation of 200 individuals (400 chromosomes) from a
anel of unrelated unaffected individuals. Control DNA was
btained from the National Institute of General Medical
ciences (NIGMS) Human Genetic Cell Repository
hrough the Coriell Institute for Medical Research, and the
ontrols were matched to the mutation carriers by ancestry.
ovel sequence variants were characterized as mutations
nly if they were absent in the unaffected controls and also
isrupted amino acids, which are highly conserved.
All consenting family members were tested for the
resence or absence of the mutation identified in the family
roband. Again, DNA was extracted from leukocytes present in
hole blood and subjected to focused bidirectional sequence
nalysis using methods described in the preceding text.
orrelation between CMR and genotype. Based on the
resence of mutation(s) in 1 or more genes encoding
esmosomal proteins, the study population was divided into
distinct groups: 1) family members with a mutation; and
) family members without a mutation. CMR characteris-
ics were compared between these subgroups.
orrelation between CMR and Task Force criteria. The
tudy population was divided into subgroups based on the
ulfillment of the Task Force criteria. One “criteria point”
as given for fulfillment of each minor criterion, and 2
riteria points were given for fulfillment of each major
riterion. Thus, ARVD/C diagnosis, according to the Task
orce definition, was made if an individual had 4 or more
riteria points. The presence of CMR characteristics was
xamined in relation to the criteria points achieved. As
amily history may provide either a major or a minor
riterion regardless of any other abnormality, total criteria
oints excluding family history were also calculated for each
ndividual in the study population.
tatistical analyses. All continuous variables were ex-
ressed as mean  SD and all categorical variables as
requency (%). Comparisons in continuous variables be-
1
1ween subgroups of patients were performed by t test.
ategorical variables were compared by the chi-square test
r Fisher exact test. Criteria points were treated as nominal
ariables for comparison between groups.
Receiver-operating characteristic (ROC) curve analysis
as used to examine the discriminatory ability of the Task
orce criteria in identifying patients with a desmosomal
utation. The presence of a desmosomal mutation was used
s a “gold standard” for this analysis. The area under the
OC curve was computed using the criteria points as
escribed above on a continuous scale ranging between 0
nd 7. The area under the ROC curve was computed again
fter incorporating the new CMR findings into the current
ask Force criteria. The 2 areas under the curves were
ompared to examine the improvement in the discriminatory
bility of the Task Force criteria after the addition of the new
ndings (26).
All statistical analyses were performed using STATA
tatistical software (version 8.2, Stata Corp., College Sta-
ion, Texas). A value of p 0.05 was considered statistically
ignificant.
esults
emographics, baseline characteristic, and genotyping. The
tudy population was composed of 38 family members from
2 families. The proband of each family was diagnosed with
RVD/C based on the Task Force criteria and carried 1 or
ore mutations in the desmosomal proteins PKP2, DSP,
nd/or DSG2. Table 1 shows the details of genetic muta-
ions present in the study population. Each of the enlisted
KP2 mutations detected in our study population has been
eported previously (11,12,16,25,27). In addition, there
ere 2 novel mutations detected in 4 individuals. A novel
utation in DSG2, V56M, was detected in an individual
arrying the 2146-1GC mutation in PKP2. Two other
amily members of this individual included in this study did
etails of Genotyping
Table 1 Details of Genotyping
Genetic Characteristic
Families
(n  12)
Individuals*
(n  38)
Presence of 1 or more mutations 9† 25
PKP2 only 8 21
1642delG 1 6
2146-1GC 2 3
2509delA 1 3
2484 CT 1‡ 3
2011delC 1 2
24891GA 1 2
F424S 1 1
S140F 1 1
PKP2 (2146-1GC) and DSG2 (V56M) 1 1
DSP (S986P) 1 3
Probands excluded are PKP2 (plakophilin 2), DSP (desmoplakin), and DSG2 (desmoglein 2).
None of the family members screened from 3 families had a mutation. The probands had the
45-148delCAGA, 1613 GA, and 2146-1 GCmutations in the PKP2 gene. ‡Three patients from
family were heterozygous for 2484 CT cryptic splice site mutation in the PKP2 gene (28).
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Genetics and CMR in Familial ARVD/C April 14, 2009:1289–99ot carry the DSG2 mutation but had 2 distinct PKP2
utations (2146-1GC and S140F). The proband (ex-
luded from the study as described in the Methods section)
ho is the father of these 3 individuals carried both the
KP2 mutations as well as the DSG2 mutation. Another
ovel mutation detected in this study was the DSP S986P,
hich was present in 3 individuals from 1 family. One of
hese individuals was diagnosed with ARVD/C (4 criteria
oints), and another individual had 3 criteria points for
RVD/C diagnosis. None of the individuals from 3 fami-
ies (other than the proband) carried a desmosomal muta-
ion. Overall, 25 (66%) of 38 family members had 1 or more
esmosomal mutations, and 13 (34%) had no detectable
esmosomal mutation.
Table 2 shows the demographics and symptoms present
t the time of screening in the study population. Although
one of these family members had sought medical advice for
hese symptoms earlier, 9 individuals had prior cardiac
ymptoms. Palpitations were more commonly present in
atients with a mutation compared to those without (p 
.05). The number of criteria points achieved by patients
ith mutation(s) was greater than those achieved by patients
ithout the mutation(s) (p  0.05).
RVD/C diagnosis. As shown in Table 2, 4 (11%) family
embers met an adequate set of criteria (4 criteria points or
reater) to establish ARVD/C diagnosis. All 4 of these
ndividuals carried a desmosomal mutation. All 13 individ-
als without a mutation achieved 2 criteria points or fewer.
n fact, barring the criteria for family history (which all
ndividuals in this study population fulfill), only 1 of these
3 individuals achieved a criteria point.
Demograhics, Prior Symptoms, Family History, aFulfillment of the Task Force Criteria (19) in the
Table 2 Demograhics, Prior Symptoms, FamFulfillment of the Task Force Criter
Characteristics
Age, yrs
Sex, male
Prior symptoms
Syncope
Palpitation*
Family history
SCD 35 yrs of age or ARVD/C by Task Force criteria
ARVD/C by histopathology evidence
Criteria points for ARVD/C diagnosis*
4
3
2
1
Criteria points excluding family history*
2
1
0
Values are expressed as n (%) or mean  SD. Criteria points were calc
fulfilled by the individual. The presence of 4 or more criteria points
(ARVD/C) diagnosis by Task Force criteria. *p  0.05 for comparison betwee
SCD  sudden cardiac death.Table 3 shows the electrophysiologic and structural char-
cteristics, as determined by noninvasive testing, used to
scertain the fulfillment of the Task Force criteria. The
resence of T-wave inversions in right precordial leads on a
2-lead electrocardiogram in individuals with a desmosomal
utation was significantly higher than that in individuals
ithout a mutation (p  0.05). Similarly, the presence of
V wall motion abnormalities in individuals with a muta-
ion appeared to be higher than that in individuals without
mutation (p  0.1).
orphologic variants of RV and LV by CMR. Detailed
MR findings of individuals included in the study are
resented in Tables 4 and 5. CMR findings were compared
etween individuals with a desmosomal mutation and those
ithout (Table 4), between individuals who met 3 criteria
oints and those with fewer criteria points (Table 5), and
nally, between individuals with 1 criteria point other
han family history and those with no criteria points other
han family history (Table 5). Individuals with 1 criteria
oint other than family history (n  13) represent those
ndividuals with any ARVD/C-related structural or electri-
al abnormality.
IGHT- VERSUS LEFT-SIDED DISEASE. As shown in Table 4,
here was a significantly reduced RVEF among individuals
ith a desmosomal mutation compared with those without
mutation. RVESV, EDV, and prevalence of quantitative
arameters such as impaired global function, hypokinesia/
kinesia, intramyocardial fat, and delayed enhancement
ere higher in individuals with a desmosomal mutation
ompared with those without. The lack of statistical signif-
dy Population
istory, and
) in the Study Population
mily Members
ith Mutation
(n  25)
Family Members
Without Mutation
(n  13)
Total
(n  38)
35 16 30 17 31 17
14 (56) 4 (31) 18 (47)
1 (4) 1 (8) 2 (5)
7 (28) 0 (0) 7 (18)
12 (48) 4 (31) 16 (42)
13 (52) 9 (69) 22 (58)
4 (16) 0 (0) 4 (11)
7 (28) 0 (0) 7 (18)
9 (36) 10 (77) 19 (50)
5 (20) 3 (23) 8 (21)
8 (32) 0 (0) 8 (21)
4 (16) 1 (8) 5 (13)
13 (52) 12 (92) 25 (66)
by adding the major (2 points each) and minor (1 point each) criteria
cative of arrythmogenic right ventricular dysplasia/cardiomyopathyndStu
ily H
ia (19
Fa
W
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April 14, 2009:1289–99 Genetics and CMR in Familial ARVD/Ccance when comparing these parameters is likely due to the
mall sample size.
On comparing the RV qualitative and quantitative pa-
ameters between individuals with 3 criteria points and
hose with fewer criteria points (Table 5), significant dif-
erences were observed in almost all qualitative parameters
nd all quantitative parameters. Individuals with 3 criteria
oints had reduced EF, increased ESV and EDV, and a
Electrical and Structural Abnormalities in the St
Table 3 Electrical and Structural Abnormalit
Characteristics
Depolarization
QRS 110 ms
Epsilon wave
Late potentials
S-wave upstroke 55 ms
Repolarization
T-wave inversions beyond V2*
Arrhythmia
1,000 PVCs on a 24-h Holter monitor
LBBB type ventricular tachycardia on a 12-lead
electrocardiogram, 24-h Holter monitor, or ETT
Structural abnormalities
Global RV dilation
RV wall motion abnormalities*†
Values expressed as n (%). *p  0.05 for comparison between family
family members with and without mutation(s).
ETT  exercise tolerance testing by Bruce protocol; LBBB  left b
ventricular.
Global and Regional Characteristics of the RighVentricles on Magnetic Resonance Imaging by M
Table 4 Global and Regional CharacteristicsVentricles on Magnetic Resonance
Characteristics
Family
With M
(n 
Right ventricle
Qualitative parameters, n (%)
Impaired function 4
Hypokinesia/akinesia 4
Intramyocardial fat* 7
Delayed enhancement 5
Accordion sign† 15
Qualitative parameters, mean  SD
End-diastolic volume 153
End-systolic volume* 73
Ejection fraction‡ 53
Left ventricle
Qualitative parameters, n (%)
Impaired function 0
Hypokinesia/akinesia 0
Intramyocardial fat 4
Delayed enhancement 0
Qualitative parameters, mean  SD
End-diastolic volume 140
End-systolic volume 54
Ejection fraction 62*p  0.1 for comparison between family members with and without mutatio
without mutation(s); ‡p  0.05 for comparison between family members witigher prevalence of qualitative abnormalities such as glo-
ally impaired function, the presence of intramyocardial fat
Online Appendix), and delayed enhancement (Online
ppendix).
Finally, on comparing the RV qualitative and quanti-
ative parameters between individuals with 1 criteria
oints and those with fewer criteria points (Table 5)
xcluding family history, significant differences were
opulation
n the Study Population
y Members
Mutation
 25)
Family Members
Without Mutation
(n  13)
Total
(n  38)
2 (8) 0 (0) 2 (5)
1 (4) 0 (0) 1 (3)
23 (13) 0/12 (0) 3/35 (9)
20 (40) 2/10 (20) 10/30 (33)
7 (28) 0 (0) 7 (20)
17 (24) 0/10 (0) 4/27 (15)
17 (12) 0/10 (0) 2/27 (7)
6 (24) 1 (8) 7 (18)
6 (24) 0 (0) 6 (16)
ers with and without mutation(s); †p  0.1 for comparison between
branch block; PVC  premature ventricular contraction; RV  right
Lefttion Carrier Status
he Right and Left
ing by Mutation Carrier Status
ers
n
Family Members
Without Mutation
(n  13)
Total
(n  38)
1 (8) 5 (13)
0 (0) 4 (11)
0 (0) 7 (18)
0 (0) 5 (13)
0 (0) 15 (39)
142 39 149 41
58 15 68 24
59 6 55 8
0 (0) 0 (0)
0 (0) 0 (0)
0 (0) 4 (11)
0 (0) 0 (0)
132 30 137 29
46 9 52 16
64 6 63 7udy P
ies i
Famil
With
(n
3/
8/
4/
2/
membt anduta
of t
Imag
Memb
utatio
25)
(16)
(16)
(28)
(20)
(60)
 42
 27
 8
(0)
(0)
(16)
(0)
 29
 18
 8n(s); †p  0.001 for comparison between family members with and
h and without mutation(s).
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Genetics and CMR in Familial ARVD/C April 14, 2009:1289–99bserved in several qualitative and quantitative parame-
ers. Individuals with 1 criteria points excluding family
istory had reduced EF, increased ESV, and a higher
revalence of qualitative abnormalities such as globally
mpaired function, the presence of intramyocardial fat,
nd delayed enhancement.
In contrast to the differences in the RV characteristics,
he LV features (other than the presence of intramyocardial
at in 4 individuals with a desmosomal mutation) were
emarkably similar when compared between subgroups
ased on mutation-carrier status (Table 4), the presence of
3 criteria points (Table 5), and the presence of 1 criteria
oint excluding family history. The only notable feature in
ll of these comparisons was the presence of intramyocardial
V fat, which was present in 4 individuals in the study
opulation. Interestingly, each of these 4 individuals carried
desmosomal mutation. Although no statistically signifi-
ant difference was noted when comparing between muta-
ion carriers and noncarriers (p  0.279), the presence of
ntramyocardial LV fat showed a tendency to correlate with
resence of 3 criteria points (p  0.065). Three of the 4
ndividuals had clinical characteristics that would qualify as
riteria points: 2 were diagnosed with ARVD/C with 5 and
criteria points, respectively, and 1 had 3 criteria points.
ne individual with the presence of intramyocardial LV fat
ad no abnormality that would qualify as a major or minor
lobal and Regional Characteristics of the Right and Left Ventricleesonance Imagi g by the Presence of Other ARVD/C-Related Abn
Table 5 Global and Regional Characteristics of the Right and LResonance Imaging by the Presence of Other ARVD/C
All Task Force Cr
Characteristics
Family Members With
<3 Criteria Points
(n  27)
F
Right ventricle
Qualitative parameters, n (%)
Impaired function 1 (4)
Hypokinesia/akinesia 1 (4)
Intramyocardial fat 0 (0)
Delayed enhancement 1 (4)
Accordion sign 7 (26)
Qualitative parameters, mean  SD
End-diastolic volume 140 33
End-systolic volume 60 15
Ejection fraction 57 7
Left ventricle
Qualitative parameters, n (%)
Impaired function 0 (0)
Hypokinesia/akinesia 0 (0)
Intramyocardial fat 1 (4)
Delayed enhancement 0 (0)
Qualitative parameters, mean  SD
End-diastolic volume 133 27
End-systolic volume 50 13
Ejection fraction 62 7
p 0.05 for comparison between family members with different criteria points; †p 0.001 for co
embers with different criteria points.
ARVD/C  arrythmogenic right ventricular dysplasia/cardiomyopathy.riterion. lHE ACCORDION SIGN. While studying the cine images of
he heart in an axial plane, a peculiar characteristic in the
ontraction pattern of the RV wall was observed in 15 of the
8 individuals in the study population. In each of these 15
ndividuals, the RVOT and/or the subtricuspid region of
he RV free wall showed a characteristic focal “crinkling,”
hich became more prominent during the systole (Fig. 1,
nline Videos 1 and 2). Although this finding is not a
ormal variant of RV morphology (28), it did not affect the
lobal RV function. The presence of this abnormality did
ot result in global RV dilation or wall motion abnormality,
nd neither did it qualify as a focal RV aneurysm (20,22,29).
e have chosen to refer to this as the accordion sign.
Interestingly, each of the 15 individuals with the accor-
ion sign had a desmosomal mutation. In fact, the accor-
ion sign was the most prevalent qualitative abnormality
60%) in individuals with desmosomal mutations, and its
revalence was significantly higher when compared with
hose without a mutation (0%) (p 0.001). The presence of
he accordion sign was higher in individuals with3 criteria
oints (73%) compared with those with fewer criteria points
26%) (p  0.05). Similarly, presence of the accordion sign
as higher in individuals with 1 criteria point excluding
amily history (70%) compared with those with no criteria
oints other than family history (24%) (p  0.05). Preva-
Magneticlities
entricles on Magnetic
ted Abnormalities
Task Force Criteria Excluding Family History
Members With
riteria Points
n  11)
Family Members With
0 Criteria Points
(n  25)
Family Members With
1 Criteria Points
(n  13)
4 (36)* 0 (0) 5 (38)*
3 (27) 1 (4) 3 (23)
7 (64)† 0 (0) 7 (54)†
4 (36)* 1 (4) 4 (31)*
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April 14, 2009:1289–99 Genetics and CMR in Familial ARVD/Cith disease severity, as determined by the number of
riteria points achieved (Fig. 2).
Because of the association of the accordion sign with
utation status as well as disease severity, further analysis was
ndertaken to examine the utility of this novel marker in
dentifying early disease. Table 6 shows the ability of the Task
orce criteria to discriminate individuals with an ARVD/C-
elated mutation from those without one. The discriminatory
bility is quantitatively measured by the area under the ROC
urve statistic. This statistic represents the probability that the
ask Force criteria assign a higher value (in terms of number of
riteria points) to mutation carriers than to noncarriers. The
alue of this statistic can range between 0 and 1, with 0.5
ndicating the inability of the Task Force criteria to identify
utation carriers from noncarriers and 1 indicating a perfect
bility to distinguish them. Values 0.5 are indicative of
dentification of mutation carriers as noncarriers and vice versa.
s shown in Table 6, the discriminatory ability of the Task
orce criteria, both including (0.68 [95% confidence interval
CI): 0.54 to 0.83] to 0.79 [95% CI: 0.73 to 0.94]; p  0.01)
nd excluding family history (0.71 [95% CI: 0.60 to 0.83] to
.84 [95% CI: 0.73 to 0.94]; p 0.01), improved significantly
fter including the presence of the accordion sign as a minor
Figure 1 The Accordion Sign
CMR image of 2 individuals demonstrating the presence of the accordion
sign in systole (A) and diastole (B). Arrows indicate the accordion sign. LV  left
ventricle; RV  right ventricle. For accompanying Videos 1 and 2 and their leg-
ends, please see the online version of this article.riterion under Structural Abnormalities.A number of additional analyses (results not shown) were
erformed to ensure reliability and validity of the results.
irst, all analyses for EDV, ESV, and EF were repeated
fter obtaining values adjusted for body surface area, and
imilar results were noted. Second, all CMRs were reviewed
or the presence of the accordion sign at 2 different time
oints, 2 weeks apart, and blinded to the initial results. All
ndividuals identified as positive for the accordion sign at
he first reading were detected as positive on the second
eading. No individual who was labeled as negative for the
ccordion sign at the first reading was detected as positive
n the second reading. Third, CMRs of the probands of
amilies included in this study were evaluated for the
resence of the accordion sign, and all probands were found
o be positive for the sign. In fact, in the more advanced
ases, the sign appeared to become more synonymous with
V free wall aneurysms, suggesting that the accordion sign
ay be a precursor of aneurysms. And finally, CMRs of 20
andomly selected disease-free individuals were evaluated
or the presence of the accordion sign, and none of these
ndividuals were positive for the sign (29).
iscussion
ain findings. In a unique and an unbiased population of
amily members of ARVD/C patients undergoing prospec-
ive evaluation for ARVD/C diagnosis, detailed examina-
ion of RV and LV morphologies was performed using the
ophisticated CMR techniques. Although the RV of the
utation carriers in the study population was significantly
ffected compared with noncarriers, the LV was affected less
requently. Despite a single case with no other abnormality,
ndividuals with LV involvement had other signs suggestive
f ARVD/C. Moreover, the LV involvement appeared to
orrelate with increasing disease severity as determined by
he presence of criteria points achieved.
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Figure 2 Accordion Sign and Disease Severity
Prevalence of the accordion sign presented by criteria points achieved for
arrythmogenic right ventricular dysplasia/cardiomyopathy diagnosis. Minor crite-
rion  1 point; major criterion  2 points.
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Genetics and CMR in Familial ARVD/C April 14, 2009:1289–99Detailed CMR imaging of the RV free wall revealed a
otential novel indicator of ARVD/C, and its utility in
dentifying individuals predisposed to developing ARVD/C
as systematically evaluated. The accordion sign was not
nly the strongest qualitative indicator differentiating mu-
ation carrying family members from noncarriers but was
lso associated with increasing disease severity. Addition of
his sign as a minor criterion significantly improved the
iagnostic utility of the currently used Task Force criteria
or ARVD/C diagnosis.
V involvement in ARVD/C. ARVD/C was first de-
cribed as a clinical entity in 1977 by Fontaine et al. (30),
nd the detailed clinical characteristics in a group of 24
RVD/C patients were first reported by Marcus et al. in
982 (1). These pioneers of ARVD/C research and other
nvestigators established ARVD/C as a cardiomyopathy
redominantly affecting the RV, and left-sidedness was
onsidered as a late manifestation of the disease. Conse-
uently, the Task Force criteria for ARVD/C diagnosis that
ere proposed in 1994 were designed to assign a criterion
or structural disease to individuals with structural RV
mpairment and “no (or only mild) LV impairment” (19).
he ensuing clinical description of ARVD/C characteristics
n several large cohorts relied on inclusion of patients who
ulfilled the Task Force criteria and therefore resulted in the
nder-representation of “left-sided arrhythmogenic cardio-
yopathy,” if such an entity in fact existed (3,4,31,32).
ong-term follow-up in large cohorts selected on the basis
f fulfillment of the Task Force criteria has demonstrated
V involvement at the advanced stages of disease progres-
ion (3,4). This finding is consistent with those demon-
trated by Corrado et al. (33) in a series of hearts from
RVD/C patients examined on autopsy or transplant.
More recently, ARVD/C has been shown to be a disease
f the cardiac desmosome (34). As the desmosomal struc-
ure is similar on the right and the left side of the heart, the
xistence of left-sided arrhythmogenic cardiomyopathy has
een hypothesized. Three studies investigating the RV and
V characteristics in relation to the presence of desmosomal
utations are particularly noteworthy. Bauce et al. (8)
eported their echocardiographic findings in 26 DSP muta-
ion carriers among 38 individuals from 4 families. Of the
4 individuals with an abnormal echocardiogram, 13 had
V involvement and 7 had LV involvement. RVEF and
VEDV were similar (or slightly worse) in patients with
Ability of the Task Force Criteria to DiscriminatMembers With and Without a Desmosomal MuInc usion of t e Acc dion Sign a a Minor Crite
Table 6
Ability of the Task Force Criteria to
Members With and Without a Desm
Inclusion of the Accordion Sign as a
Withou
Task Force criteria 0.6
Task Force criteria excluding family history 0.7V involvement, and only 1 individual had an abnormal LV dith no abnormalities detected in the RV. In a subgroup
f 22 mutation carriers among 28 genotyped individuals
ho underwent CMR with delayed enhancement, Sen-
howdhry et al. (35) reported LV delayed enhancement in
00% of the mutation carriers. In the same study, 54% of
he mutation carriers were reported to have LV systolic
ysfunction. Subsequently, the same group reported LV
nvolvement in 85% and predominantly left-sided disease in
5% of the 39 desmosomal mutation carriers (18). Similar
V involvement was reported in a larger cohort of 200
esmosomal mutation carrying and noncarrying individuals.
election of the study population relied on fulfillment of the
ask Force and the “modified criteria.”
Similar to the reports by Sen-Chowdhry et al. (35), our
tudy utilized state-of-the-art CMR protocols to character-
ze myocardial tissue as well as fat and fibrosis. Consistent
ith their findings, the RV and LV function, as determined
y EDV and EF, was relatively preserved in our study
opulation regardless of the mutation carrier status. How-
ver, the qualitative findings of our study sharply contrast
ith those of Sen-Chowdhry et al. (35). The frequency of
ach qualitative characteristic of ARVD/C in the RV and
V was substantially lower in our study population. The
ost notable was the absence of LV delayed enhancement
n any individuals in our study population as opposed to
early all individuals in their report. The only qualitative LV
bnormality noted in our study population was the presence
f LV intramyocardial fat in 4 mutation carriers. The
eft-sidedness of the disease demonstrated by our study is
omewhat similar to that reported by Bauce et al. (8). The
esults of both studies demonstrate LV involvement in a
mall fraction of family members of ARVD/C patients that
re more predisposed to developing the disease (as deter-
ined by mutation-carrier status). In both studies, there was
nly 1 individual with an LV abnormality on imaging who
emonstrated no other ARVD/C-related abnormality.
There are several possible reasons for these observed
ifferences between our results and those reported by
en-Chowdhry et al. (18) among individuals selected based
n fulfillment of Task Force criteria and the “modified
riteria.” First, our study design was leveraged by a system-
tic inclusion of family members of ARVD/C patients who
ould have otherwise not sought medical attention. This
ethod of selection of the study population ensured the
nclusion of individuals who would be equally likely to
ween FamilyB fore and AfterUnde “Structural Abnormalities”
riminate Between Family
al Mutation Before and After
or Criterion Under “Structural Abnormalities”
a Under the Curve (95% Confidence Interval)
rdion Sign With Accordion Sign p Value
–0.83) 0.79 (0.73–0.94) 0.0059
–0.83) 0.84 (0.73–0.94) 0.0046e Betationrion
Disc
osom
Min
Are
t Acco
8 (0.54
1 (0.60evelop RV and LV abnormalities. It has been previously
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April 14, 2009:1289–99 Genetics and CMR in Familial ARVD/Chown that ARVD/C is a gradually progressive disease, and
here can be a substantial lag time between the initial signs
f the disease and diagnosis based on the Task Force criteria
4). It is likely that individuals with a Task Force diagnosis,
s was the case in the study by Sen-Chowdhry et al. (18),
ould have substantially more advanced disease compared
ith family members undergoing prospective clinical and
enetic screening. If the LV were involved at advanced
tages of the ARVD/C as proposed initially, then there
ould have been an over-representation of such cases in
heir study population. Second, although the inclusion of
ndividuals who fulfill the modified Task Force criteria
nsures inclusion of early cases of ARVD/C, it may have
esulted in a loss of specificity with inclusion of patients
ith other types of cardiomyopathies. For example, under
he proposed modified criteria, an individual with a family
istory of ARVD/C with 200 ventricular ectopics would
ualify for an ARVD/C diagnosis (32). And a final poten-
ial explanation for the differing results between the 2 studies
s reflected in the differing frequencies of desmosomal muta-
ions in the 2 study samples. While a majority of individuals in
he study by Sen-Chowdhry et al. (18) had a DSP mutation,
he most common desmosomal mutation in our study popu-
ation was in PKP2. The mechanism by which each of these
esmosomal proteins results in ARVD/C is largely unknown,
nd it is possible that these genes affect the 2 ventricles
ifferentially.
The low prevalence of LV involvement observed in our
tudy population does not rule out the possibility of LV
nvolvement at early stages of ARVD/C, but it underscores
he low possibility of such occurrence. In fact, the presence
f desmosomal mutation(s) in each of the 4 individuals with
V involvement substantiates such a possibility. Consistent
ith the report by Bauce et al. (8), each of these 4
ndividuals had inferior lead T-wave inversion on a 12-lead
lectrocardiogram.
Minimal LV involvement is also consistent with animal
odels of ARVD/C. Basso et al. (36) studied the charac-
eristics of ARVD/C in 23 boxer dogs and found his-
opathologic evidence of the disease in the LV of 11 dogs.
V involvement independent of RV involvement was not
eported in any of the animals. Subsequently, Oxford et al.
37) confirmed and extended these findings in a group of 12
RVD/C boxer dogs. Although immunochemical analysis
f intercalated disc proteins in the heart tissue of these dogs
evealed a loss of the spatial organization of the molecular
omponents in both RV and LV, the overall myocardial
rchitecture in the LV was better preserved compared with
he RV, which showed remarkable fibrofatty replacement.
aplan et al. (38,39) have proposed that disruption of
ell-to-cell coupling between the adjacent myocytes may
recede fibro-fatty replacement. In this regard, the RV wall,
hich is thinner and more susceptible to mechanical stress,
s more likely to get affected compared with the LV. Finally,
irchhof et al. (40) demonstrated that the RV and not the
V was significantly affected in plakoglobin-deficient mice. phe LV size and function remained preserved despite
ndurance training in these mice. Studies in humans, which
ely on imaging in vivo rather than detailed histopathology
nd immunochemistry, are likely to detect even less evi-
ence of morphologic alterations as described by these
tudies.
he accordion sign. Detailed CMR study of the RV free
all revealed the presence of a new morphologic variant,
hich is associated with the presence of desmosomal mu-
ations as well as disease severity. Marcus et al. (1), in their
nitial observational study of 24 patients, specifically iden-
ified 3 major regions of the RV that were affected earliest
y ARVD/C. These 3 areas, collectively known as the
riangle of dysplasia, constituted the inferior tricuspid, the
utflow tract, and the apical areas of the RV. The presence
f the accordion sign in the inferior tricuspid and basal RV
s consistent with these areas conventionally known to be
he most affected.
The majority of the mutations reported in this study have
een previously reported to cosegregate with ARVD/C
14,27). The novel DSP mutation reported in this study
osegregated with ARVD/C among 2 individuals within a
amily, and the novel DSG2 mutation was present in an
ndividual who already had a detrimental PKP2 mutation.
lthough these mutations appear to have a low penetrance
hen ARVD/C is diagnosed by the Task Force criteria
12), there is a much higher probability of mutation carriers
aving ARVD/C-related abnormalities resulting in an in-
omplete set of Task Force criteria (8,14). The presence of
hese mutations can therefore be used as a surrogate for the
igh probability of individuals developing the disease. The
ccordion sign was the single most consistent qualitative
eature that could identify mutation carriers with a sensitiv-
ty of 60% and 100% specificity. The association between
he accordion sign and the presence of any criterion other
han family history highlights its importance as an early sign
f the disease. Incorporation of the accordion sign also
ignificantly improves the discriminatory ability of the
urrent Task Force criteria in identifying desmosomal mu-
ation carriers. The readers of CMR studies were blinded to
he clinical and genetic data and were unlikely to be biased
y such results.
tudy limitations. Studies on ARVD/C, in particular the
enetic studies, are typically small in size. Our study sample
ay have been underpowered to detect certain morphologic
ifferences between mutation carriers and noncarriers.
oreover, the relatively low prevalence of DSG2 and the
SP mutation restricted our ability to compare the mor-
hologic variants by the gene(s) involved. We were also
nable to make comparisons by severity of the desmosomal
utations. Finally, our results demonstrate the incremental
alue of CMR in predicting a desmosomal mutation or the
resence of the Task Force criteria and not the ARVD/C
henotype.
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he results of our study underscore the ability of CMR to
etect early morphologic changes in ARVD/C. ARVD/C
ssociated with desmosomal mutations can involve both the
ight and the left side of the heart. Despite LV involvement,
he overall structure and function is well preserved in the
arly stages of the disease. Independent LV involvement is
rare occurrence and is consistent with the traditional
otion that right-sided disease precedes left-sided disease in
he majority of the cases. The accordion sign is a possible
arly morphologic variant of ARVD/C and is a promising
ool for early diagnosis of the disease. Its prevalence and
iagnostic utility should be confirmed in larger cohorts of
genotyped and nongenotyped) ARVD/C patients. Objec-
ive methods to assess its presence using techniques such as
yocardial tagging should be developed.
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